Mark J Mulligan MD FIDSA

HIV/AIDS Medicine, Microbiology

Director, NYU Langone Vaccine Center; Director, Division of Infectious Diseases and Immunology; Thomas S. Murphy, Sr. Professor of Medicine; Professor of Microbiology; Department of Medicine, NYU Langone School of Medicine

Join to View Full Profile

NYU Langone Medical Center - Infectious Diseases and ImmunologyAlexandria Center for Life Sciences (West Tower) 430 E 29th St, Room 304New York, NY 10016
Phone+1 212-263-9410
Fax+1 646-501-4645

Education & Training

University of Alabama Medical CenterFellowship, Infectious Disease, 1987 - 1990
University of Alabama Medical CenterResidency, Internal Medicine, 1984 - 1987
University of Texas Southwestern Medical SchoolClass of 1984

Certifications & Licensure

NY State Medical License 2018 - 2026
GA State Medical License 2006 - 2019
AL State Medical License 1985 - 2006
TX State Medical License 1985 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

A Study to Test the Safety of Three Experimental HIV Vaccines
Completed
Phase 1
Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults
Completed
Phase 1
Yellow Fever Virus Vaccine and Immune Globulin Study Start of enrollment: 2006 Jun 01
Completed
Phase 1
Human Immune Responses to Yellow Fever Vaccination Start of enrollment: 2008 May 01
Recruiting
Phase 4
Systems Biology of PNEUMOVAX®23 and PREVNAR 13® Start of enrollment: 2014 Apr 01
Completed
Not Applicable
Immune Memory After Papillomavirus Vaccination Start of enrollment: 2012 Jan 01
Completed
Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics Start of enrollment: 2015 Apr 01
Completed
Not Applicable
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
Completed
Phase 2
Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies Start of enrollment: 2015 Oct 28
Completed
Phase 1
2013/2017 H7N9 Prime-Boost Interval Start of enrollment: 2018 Aug 21
Completed
Phase 2
New York City Observational Study of Mpox Immunity Start of enrollment: 2022 Nov 11
ENROLLING_BY_INVITATION
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response.
Aaron L Oom, Kesi K Wilson, Miilani Yonatan, Stephanie Rettig, Heekoung Allison Youn
Journal of Virology. 2025-03-31
1 citations
System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans.
Mario Cortese, Thomas Hagan, Nadine Rouphael, Sheng-Yang Wu, Xia Xie
Nature Immunology. 2025-01-01
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults.
Varun K Phadke, Daniel J Gromer, Paulina A Rebolledo, Daniel S Graciaa, Zanthia Wiley
Vaccine. 2024-12-02

Press Mentions

Why This Flu Season Is so SevereFebruary 19th, 2025
5 Unusual Covid Symptoms — and What to Do About ThemNovember 16th, 2022
Meissa Appoints Drs. Dan H. Barouch and Mark J. Mulligan to Scientific Advisory BoardDecember 16th, 2021
Join now to see all

Grant Support

Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)NEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2026
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)NEW YORK UNIVERSITY SCHOOL OF MEDICINE2020–2026
Clinical And StatisticalNational Institute Of Allergy And Infectious Diseases2011
Training A New Generation Of VaccinologistsNational Institute Of Allergy And Infectious Diseases2009–2011
Clinical And StatisticalNational Institute Of Allergy And Infectious Diseases2009–2011
Vaccine And Treatment Evaluation UnitsNational Institute Of Allergy And Infectious Diseases2009
Clinical Research CoreNational Institute Of Allergy And Infectious Diseases2008
Alabama/Zambia HIV Vaccine Clinical Trials Unit (HVTU)National Institute Of Allergy And Infectious Diseases2000–2003
AIDS Vaccine Evaluation UnitsNational Institute Of Allergy And Infectious Diseases1994–2000
Glycoproteins In HIV-2 Assembly, Binding, And FusionNational Institute Of Allergy And Infectious Diseases1994–1996
HIV-2 Envelope Glycoproteins And Cell FusionNational Institute Of Allergy And Infectious Diseases1988–1992